Video

Dr. Grünwald on depth of response and efficacy with pembrolizumab/lenvatinib in renal cell carcinoma

The phase 3 CLEAR trial showed that frontline therapy with pembrolizumab (Keytruda) plus lenvatinib (Lenvima) reduced the risk of death by 34% versus sunitinib (Sutent) in patients with advanced renal cell carcinoma.

In this video, Viktor Grünwald, MD, University Hospital Essen, Germany, discusses an analysis shared at the 2021 ASCO Annual Meeting which explored efficacy in the CLEAR trial according to selected subgroups, as well as the association between depth of response and overall survival. (J Clin Oncol 39, 2021 [suppl 15; abstr 4560])

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
© 2025 MJH Life Sciences

All rights reserved.